Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTate & Lyle Regulatory News (TATE)

Share Price Information for Tate & Lyle (TATE)

Share Price is delayed by 15 minutes
Get Live Data
505.00    4.50 (0.90%)
Bid:
505.00
Ask:
505.50
Spread: 0.50 (0.099%)
Market Cap: £2.23b
TATE Live PriceLast checked at - London Stock Exchange

Intraday Tate & Lyle Share Chart

Director Declaration

10 Nov 2025 14:40

RNS Number : 9211G
Tate & Lyle PLC
10 November 2025
 

10 November 2025

 

Tate & Lyle PLC

 

 

DIRECTOR DECLARATION

 

Notification regarding external directorships

 

In accordance with Listing Rule 6.4.9(2), Tate & Lyle PLC announces that Sarah Kuijlaars, Chief Financial Officer, has notified the Company that she has been appointed as a non-executive director of JD Sports Fashion Plc (with effect from 10 November 2025).

 

On appointment, Sarah will become a member of the Audit and Risk Committee and the Nomination Committee. Sarah will be appointed as Chair of the Audit and Risk Committee with effect from 1 June 2026.

 

 

END

 

For more information contact:

 

For Tate & Lyle PLC

 

Investors and analysts

Christopher Marsh, VP Investor Relations

Tel: Mobile: +44 (0) 7796 192 688

 

Media

Nick Hasell, FTI Consulting

Tel: Mobile: +44 (0) 7825 523 383

Tel: Office: +44 (0) 203 727 1340

Email: tate@fticonsulting.com

 

About Tate & Lyle PLC:

 

Supported by our 165-year history of ingredient innovation, we partner with customers to provide consumers with healthier and tastier choices when they eat and drink. We are proud that millions of people around the world consume products containing our ingredients and solutions every day.

 

Through our leading expertise in sweetening, mouthfeel and fortification, we develop ingredients and solutions which reduce sugar, calories and fat, add fibre and protein, and provide texture and stability to food and drink in categories including beverages, dairy, bakery, snacks, soups, sauces, and dressings.

 

Tate & Lyle recently acquired CP Kelco, a leading provider of pectin, speciality gums and other nature-based ingredients to create a leader in mouthfeel, significantly enhancing our solutions capabilities. Following this combination, we now have more than 5,000 employees working in around 75 locations in 38 countries, serving customers in more than 120 countries. Science, Solutions, Society is our brand promise and how we will achieve our purpose of Transforming Lives through the Science of Food. By living our purpose, we believe we can successfully grow our business and have a positive impact on society. We live our purpose in three ways, by supporting healthy living, building thriving communities and caring for our planet.

 

Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. For the year ended 31 March 2025, and on a pro forma basis which assumes for illustrative purposes that the combination with CP Kelco took place on 1 April 2024, revenue for the enlarged Tate & Lyle Group would have been £2.12 billion. For more information, please visit www.tateandlyle.com or follow Tate & Lyle on LinkedInX (Twitter)Facebook or YouTube.

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RDNZBLFFEFLXFBK
Date   Source Headline
29th May 20263:58 pmRNSForm 8.5 (EPT/RI)-Tate & Lyle plc Amend
29th May 20261:32 pmRNSForm 8.3 TATE & LYLE PLC
29th May 202612:00 pmRNSForm 8.5 (EPT/RI)-TATE & LYLE PLC
29th May 202611:31 amRNSForm 8.5 (EPT/NON-RI)-TATE & LYLE PLC
29th May 202610:59 amRNSForm 8.5 (EPT/NON-RI)-Tate & Lyle plc
29th May 202610:59 amRNS20260528_TATE & LYLE_8.5 EPT RI_UK_MLI
29th May 202610:54 amRNSForm 8.5 (EPT/RI)-Tate & Lyle plc
29th May 202610:26 amBUSForm 8.3 - Tate & Lyle PLC
29th May 202610:13 amRNSForm 8.3 - Tate & Lyle PLC
29th May 20269:13 amRNSForm 8.3 - Tate & Lyle plc
29th May 20268:48 amRNSForm 8.5 (EPT/RI)
28th May 20264:46 pmRNSForm 8.3 - Tate & Lyle Plc Amendment
28th May 20264:43 pmRNSForm 8.3 - Tate & Lyle Plc Amendment
28th May 20264:40 pmRNSForm 8.5 (EPT/RI)-Tate & Lyle plc Amend
28th May 20263:20 pmRNSForm 8.3 - Tate & Lyle plc
28th May 20263:18 pmRNSForm 8.3 TATE & LYLE PLC
28th May 20262:58 pmRNSForm 8.3 Tate & Lyle Plc
28th May 20262:55 pmRNSForm 8.3 - Tate & Lyle plc
28th May 20262:33 pmRNSForm 8 (OPD) (TATE & LYLE PLC)
28th May 20262:24 pmEQSForm 8.3 - The Vanguard Group, Inc.: Tate & Lyle plc
28th May 20261:37 pmRNSForm 8.3 - Tate & Lyle Plc
28th May 202611:48 amRNSForm 8.5 (EPT/NON-RI) - Tate & Lyle PLC
28th May 202611:46 amRNSForm 8.5 (EPT/RI) - TATE & LYLE PLC
28th May 202611:08 amRNSForm 8.5 (EPT/NON-RI)-Tate & Lyle plc
28th May 202611:07 amRNSForm 8.5 (EPT/NON-RI)-Tate & Lyle plc
28th May 202611:02 amRNSForm 8.5 (EPT/RI)-Tate & Lyle plc
28th May 202610:59 amRNS20260527_TATE & LYLE_8.5 EPT NON-RI_UK_BOFASE
28th May 202610:58 amRNS20260527_TATE & LYLE_8.5 EPT RI_UK_MLI
28th May 202610:35 amRNSForm 8.3 - Tate & Lyle PLC
28th May 20269:25 amRNSForm 8.5 (EPT/RI)
27th May 20264:55 pmPRNForm 8.3 - Tate & Lyle PLC
27th May 20263:25 pmRNSForm 8.3 - TATE & LYLE PLC
27th May 20263:20 pmRNSForm 8.3 - Tate & Lyle plc
27th May 20262:54 pmEQSForm 8.3 - The Vanguard Group, Inc.: Tate & Lyle plc
27th May 20262:15 pmRNSRule 2.9 Announcement
27th May 20262:11 pmRNSForm 8.3 - Tate & Lyle Plc
27th May 20261:56 pmRNSForm 8.3 TATE & LYLE PLC
27th May 20261:22 pmRNSForm 8.5 (EPT/RI)-Tate & Lyle plc Amend
27th May 202612:08 pmRNSForm 8.3 - Tate & Lyle plc
27th May 202612:03 pmRNSForm 8.5 (EPT/RI) - TATE & LYLE PLC
27th May 202612:00 pmRNSForm 8.3 - Tate & Lyle plc
27th May 202611:38 amRNSForm 8.5 (EPT/NON-RI) - Tate & Lyle PLC
27th May 202611:32 amRNSForm 8.5 (EPT/NON-RI)-Tate & Lyle plc
27th May 202611:25 amRNSForm 8.3 – Tate & Lyle PLC
27th May 202611:23 amRNSForm 8.5 (EPT/RI)-Tate & Lyle plc
27th May 202611:22 amRNSForm 8.3 – Tate & Lyle PLC
27th May 202610:58 amRNS20260526_TATE & LYLE_8.5 EPT NON-RI_UK_BOFASE
27th May 202610:57 amRNS20260526_TATE & LYLE_8.5 EPT RI_UK_MLI
27th May 202610:20 amRNSForm 8.5 (EPT/RI)
27th May 20269:45 amRNSForm 8.3 - Tate & Lyle PLC

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.